PO.MCB11.01 · 分子与细胞生物学

第二位点拯救突变体作为揭示p53癌症突变体重激活机制的工具

Second site rescue mutants as tools to uncover reactivation mechanisms of p53 cancer mutants

海报缩略图:第二位点拯救突变体作为揭示p53癌症突变体重激活机制的工具
编号 604 展板 9 时间 4/19 02:00–05:00 区域 Section 25 主讲 Fiona Law, BS
分会场 Tumor Suppressors
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Fiona Law, Zane Norman, Mark Villamil, Peter Kaiser

Uc-Irvine, Irvine, CA

摘要 Abstract

中文摘要
TP53是一种重要的抑癌基因,也是人类癌症中最常见的突变基因。大部分p53突变的癌症携带错义突变,因此它们表达全长但无功能的p53。因此,将突变的p53重新激活为类似野生型的构象长期以来一直是主要的治疗目标。然而,p53重激活的机制仍知之甚少。为剖析这一机制,本研究采用了一种遗传策略,即在癌症中发现的G245S突变之外,再突变第二个氨基酸。这第二个突变诱导结构变化,以补偿p53癌症突变所导致的缺陷。本研究使用了两种第二位点拯救突变:已知可稳定p53的N239Y,以及位于与小分子结合相关的瞬时L1/S3口袋内的T123P。当与癌症突变G245S共同表达时,两种第二位点拯救突变均恢复了抑癌特性,包括抑制生长、激活经典p53下游靶点,以及在体外和细胞内恢复DNA结合。差示扫描荧光法证实N239Y提高了G245S突变体的折叠稳定性。然而,尽管T123P拯救了p53活性,它却进一步破坏了G245S突变体的结构稳定性。这些发现表明,p53重激活可通过不同且机制上相异的途径发生,包括那些不依赖于整体热稳定化的途径。我们的结果提供了一个遗传框架,用以对p53癌症突变体的重激活机制进行分类,并定义与每种机制相关的基因表达特征。该框架并非直接的治疗手段,而是有助于指导未来p53小分子重激活剂的鉴定与开发。
查看英文原文 English abstract
TP53 is an important tumor suppressor and is the most frequently mutated gene in human cancer. A large fraction of cancers with mutated p53 carry missense mutations, so they express full-length but nonfunctional p53. Therefore, reactivating mutated p53 to a wildtype-like conformation has long been a major therapeutic goal. However, the mechanisms underlying p53 reactivation are still poorly understood. To dissect this mechanism, this study employs a genetic strategy in which a second amino acid is mutated in addition to the G245S mutation found in cancer. This second mutation induces structural changes to compensate for the defect caused by p53 cancer mutations. Two second site rescue mutations were used in this study: N239Y, known to stabilize p53, and T123P, located within the transient L1/S3 pocket implicated in small molecule binding. When expressed alongside the cancer mutation G245S, both second site rescue mutations restored tumor suppressive properties, including suppressed growth, activated canonical p53 downstream targets, and restored DNA binding both in vitro and in cells. Differential scanning fluorimetry confirmed that N239Y increased folding stability of the G245S mutant. However, despite rescuing p53 activity, T123P further destabilized the structural stability of the G245S mutant. These findings demonstrate that p53 reactivation can occur through distinct and mechanistically divergent pathways, including those independent of global thermostabilization.Our results provide a genetic framework to classify reactivation mechanisms of p53 cancer mutants and define gene-expression signatures associated with each mechanism. Rather than being a direct treatment, this framework can help guide the identification and development of future small molecule p53 reactivators.
利益披露 Disclosure
F. Law, None.. Z. Norman, None.. M. Villamil, None. P. Kaiser, Elephant Bio Stock Option, Patent.

← 返回 AACR 2026 检索